EULAR干燥综合征患者报告指数(ESSPRI)替代应答者定义(RD)的制定与验证
本研究利用锚定法和分布法,在190例中重度系统性原发性干燥综合征患者的IIb期盲态数据中推导ESSPRI替代应答者定义阈值,并在3项早期II期试验的126例盲态汇总数据中验证。未盲分析显示修订后的应答者定义(较基线改善≥1.5分且ESSPRI≤3分)可降低安慰剂应答率。
要点
- 在IIb期数据中,ROC法支持MCII阈值为1.5-1.6分。
- 低/极低症状严重度阈值≥2分获相关性加权平均变化估计支持,≤3分显示最佳敏感度/特异度平衡。
- 汇总数据支持MCII阈值1.5-2.1分、低/极低症状严重度阈值2.7-3.7分,未盲分析证实修订RD降低安慰剂应答率。
核心结论
- 完成试验时较基线改善≥1.5分且ESSPRI评分≤3分是中重度系统性干燥综合征的相关应答者定义,可降低安慰剂应答率。
研究设计与样本
- 在190例中重度系统性原发性干燥综合征患者的IIb期盲态试验数据中,采用锚定法和分布法推导应答者定义阈值。
- 在3项早期II期试验的126例盲态汇总数据中验证上述阈值。
- 锚点按ESSPRI相关性排序,并在相似条件下使用,与3名专家讨论三角化估计。
- 使用未盲数据比较修订版与原始应答者定义的安慰剂及治疗应答率。
主要发现
- 患者以女性为主(>90%)、白人(90%),平均年龄50岁。
- IIb期数据中ROC估计支持MCII阈值为1.5-1.6分,相关性加权平均变化估计支持低/极低症状严重度阈值为≥2分。
- 低/极低症状严重度≤3分显示最佳敏感度/特异度平衡。
- 汇总数据分析支持这些阈值:MCII为1.5-2.1分,低/极低症状严重度为2.7-3.7分。
- 未盲分析证实修订后的应答者定义降低了安慰剂应答率。
关键数值与推荐
- 修订后的应答者定义:较基线改善≥1.5分且ESSPRI评分≤3分。
- IIb期数据MCII阈值:1.5-1.6分。
- 汇总数据MCII阈值:1.5-2.1分。
- 汇总数据低/极低症状严重度阈值:2.7-3.7分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Dryness, fatigue and joint/muscle pain are typically assessed in Sjögren's trials using European Alliance of Associations for Rheumatology Sjögren's Syndrome Patient Reported Index (ESSPRI). A Patient Acceptable Symptom State of <5 and a Minimal Clinically Important Improvement (MCII)/responder definition (RD) of ≥1 point or 15% on ESSPRI have previously been defined. This study explored alternative RDs to better discriminate between active treatment and placebo in trials. METHODS: Anchor-based and distribution-based methods were used to derive RD thresholds in blinded phase IIb trial data (N=190) and confirm these in blinded data pooled from three early phase II trials (N=126). The populations consisted of individuals with moderate-to-severe systemic primary Sjögren's. Anchors were prioritised by ESSPRI correlations and used in similar conditions. Triangulated estimates were discussed with experts (N=3). The revised RD was compared with the original using unblinded data to assess placebo and treatment responder rates. RESULTS: Patients were predominantly female (>90%), white (90%), with mean age of 50 years. Receiver operating characteristic estimates supported an MCII threshold of 1.5-1.6 in the phase II data, whereas correlation-weighted mean change estimates supported a low/minimal symptom severity threshold of ≥2. A low/minimal symptom severity of ≤3 showed the greatest sensitivity/specificity balance. Analyses in the pooled data supported these thresholds (MCII: 1.5-2.1; low/minimal symptom severity: 2.7-3.7). Unblinded analyses confirmed the revised RD reduced placebo rates. CONCLUSIONS: Completing a trial with an improvement of ≥1.5 points compared with baseline and an ESSPRI score of ≤3 points is a relevant RD for moderate-to-severe systemic Sjögren's and reduces placebo rates.
引用
- Wratten S, Abetz-Webb L, Arenson E, et al. Development and testing of an alternative responder definition for EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). RMD Open. 2023. PMID: 36931685. doi:10.1136/rmdopen-2022-002721
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。